Processing

Please wait...

Settings

Settings

Goto Application

1. WO2008070350 - METHODS AND COMPOSITIONS RELATED TO WRAPPING OF DEHYDRONS

Publication Number WO/2008/070350
Publication Date 12.06.2008
International Application No. PCT/US2007/082893
International Filing Date 29.10.2007
IPC
C07D 401/14 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
A61K 31/506 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
A61P 35/02 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
CPC
A61K 31/506
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
C07D 401/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring-member bond
Applicants
  • THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM [US]/[US] (AllExceptUS)
  • RICE UNIVERSITY [US]/[US] (AllExceptUS)
  • FERNANDEZ, Ariel [US]/[US] (UsOnly)
  • BORNMANN, William [US]/[US] (UsOnly)
  • LOPEZ-BERESTEIN, Gabriel [US]/[US] (UsOnly)
  • SANGUINO, Angela [US]/[US] (UsOnly)
  • PENG, Zhenghong [US]/[US] (UsOnly)
Inventors
  • FERNANDEZ, Ariel
  • BORNMANN, William
  • LOPEZ-BERESTEIN, Gabriel
  • SANGUINO, Angela
  • PENG, Zhenghong
Agents
  • LANDRUM, Charles, P.
Priority Data
60/863,25527.10.2006US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS AND COMPOSITIONS RELATED TO WRAPPING OF DEHYDRONS
(FR) PROCÉDÉS ET COMPOSITIONS LIÉS AUX ENVELOPPEMENTS DE DÉSHYDRONS
Abstract
(EN)
This application describes a novel technology in drug discovery and drug-based imaging/detection: the wrapping technology. This technology is based on identified singularities in the structure of soluble proteins. In contrast with drug-design approaches based on standard structural considerations, the packing of a protein, or more precisely, its dehydron pattern, may be used as a selectivity filter to design small-molecule inhibitors. The wrapping technology described herein is a novel form of rational drug design for avoiding side effects in drug therapy and sharpening the inhibitory impact of drugs on the oncokinome.
(FR)
L'invention concerne une nouvelle technologie dans la découverte de médicaments et l'imagerie/détection à base de médicaments : la technologie d'enveloppement. Cette technologie est basée sur des singularités identifiées dans la structure de protéines solubles. Contrairement à des approches de conception de médicament basées sur des considérations structurelles types, le garnissage d'une protéine, ou plus précisément son motif déshydron peut être utilisé comme filtre sélectif pour concevoir des inhibiteurs à petite molécule. La technologie d'enveloppement décrite ici est une nouvelle forme de conception rationnelle de médicaments pour éviter les effets secondaires de la thérapie médicamenteuse et affiner l'impact inhibiteur des médicaments sur l'oncokinome.
Latest bibliographic data on file with the International Bureau